Oxidants and antioxidants in atherosclerosis

Current Opinion in Lipidology

Volumn 12, Issue 4, 2001, Pages 411-418

  Mashima, Ryuichi ^a   Witting, Paul K ^a   Stocker, Roland ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CAROTENOID; ISOPROSTANE DERIVATIVE; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; NITRIC OXIDE; OXIDIZING AGENT; PEROXY RADICAL; PEROXYNITRITE; PROBUCOL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TOCOPHEROL; TOCOPHEROXYL RADICAL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; HUMAN; LIPID PEROXIDATION; LIPOPROTEIN METABOLISM; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THEORY;

ANTIOXIDANTS; ARTERIOSCLEROSIS; FREE RADICALS; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; NITRIC OXIDE; OXIDANTS; PEROXIDASE; PROBUCOL; VITAMIN E;

EID: 0034923981     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200108000-00007     Document Type: Review

References (106)

1. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity
2. The oxidative modification hypothesis of atherogenesis: An overview
3. Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis
4. Dietary and pharmacological antioxidants in atherosclerosis
5. A comparison of the antiatherogenic effects of probucol and a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits
6. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants
7. Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits
8. Site-specific anti-atherogenic effect of probucol in apolipoprotein E deficient mice
9. Genetic modifiers of atherosclerosis in mice
10. Mass spectrometric quantification of amino acid oxidation products in proteins: Insights into pathways that promote LDL oxidation in the human artery wall
11. A role for endothelial cell lipoxygenase in the oxidative modification of low-density lipoprotein
12. Macrophages require both iron and copper to oxidize low-density lipoprotein in Hanks' balanced salt solution
13. Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase
14. Heterolytic versus homolytic peroxide bond cleavage by sperm whale myoglobin and myoglobin mutants
15. The nature of reactive species in systems that produce peroxynitrite
16. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques
17. Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque
18. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease
19. Mechanisms of free radical oxidation of unsaturated lipids
20. Detection and characterization of lipid hydroperoxides at picomole levels by high-performance liquid chromatography
21. Regioisomeric distribution of cholesteryl linoleate hydroperoxides and hydroxides in plasma from healthy humans provides evidence for free radical-mediated lipid peroxidation in vivo
22. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that correlates with lipid peroxidation and can be enhanced by α-tocopherol
23. Oxidation of high density lipoproteins. II. Evidence for direct reduction of HDL lipid hydroperoxides by methionine residues of apolipoproteins AI and AII
24. Reduction of phosphatidylcholine hydroperoxide by apolipoprotein A-I: Purification of the hydroperoxide-reducing proteins from human blood plasma
25. Human atherosderotic plaque contains both oxidized lipids and relatively large amounts of α-tocopherol and ascorbate
26. Tocopherol-mediated peroxidation (TMP) of lipoproteins implications for vitamin E as a potential antiatherogenic supplement
27. 15-Lipoxygenase-induced enzymic oxidation of low density lipoprotein associated free fatty acids stimulates nonenzymic, α-tocopherol-mediated peroxidation of cholesteryl esters
28. Molecular action of vitamin E in lipoprotein oxidation: Implications for atherosclerosis
29. Inhibition by a co-antioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice
30. Anti-atherogenic effect of coenzyme Q10 in apolipoprotein E gene knockout mice
31. Dietary co-supplementation with vitamin E and coenzyme Q10 inhibits atherosclerosis in apolipoprotein E gene knockout mice
32. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice
33. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit
34. Oxygenation of lipoproteins by mammalian lipoxygenases
35. 2α
36. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo
37. 2-isoprostanes in human urine
38. The generation and actions of isoprostanes
39. Indices of lipid peroxidation in vivo: Strengths and limitations
40. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice
41. The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis
42. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide
43. Carbon dioxide enhancement of peroxynitrite-mediated protein tyrosine nitration
44. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima
45. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits
46. Enhanced atherosclerosis and kidney dysfunction in eNOS-/-Apoe-/- mice are ameliorated by enalapril treatment
47. Biomarkers of myeloperoxidase-derived hypochlorous acid
48. Nitric oxide trapping of the tyrosyl radical of prostaglandin H synthase-2 leads to tyrosine iminoxyl radical and nitrotyrosine formation
49. Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration
50. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein
51. 2-chloride system of phagocytes, covalently modifies ε-amino groups of protein lysine residues
52. Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atheroscterotic lesions
53. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man
54. Monodonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins
55. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions
56. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis
57. Atherosclerosis: The road ahead
58. Autoxidation of human low density lipoprotein: Loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes
59. Co-existence of oxidized lipids and α-tocopherol in all lipoprotein fractions isolated from advanced human atherosclerotic plaques
60. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glyceraldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive α-hydroxy and α,β-unsaturated aldehydes by phagocytes at sites of inflammation
61. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma
62. Increased atherosclerosis in myeloperoxidase-deficient mice
63. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes
64. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial
65. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
66. Vitamin E supplementation and cardiovascular events in high-risk patients
67. Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE)
68. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)
69. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice
70. Dietary β-carotene and α-tocopherol combination does not inhibit atherogenesis in an ApoE-deficient mouse model
71. Vitamin E: Function and metabolism
72. A novel human tocopherol-associated protein: Cloning, in vitro expression, and characterization
73. Increased atherosclerosis in hyperlipidemic mice deficient in α-tocopherol transfer protein and vitamin E
74. Vitamin E and vascular homeostasis: Implications for atherosclerosis
75. Specific cellular responses to α-tocopherol
76. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells
77. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia
78. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report
79. Probucol-associated tachyarrhythmic events and QT prolongation: Importance of gender
80. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits
81. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?
82. Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hypedipidemic rabbits
83. The effect of pharmacological doses of different antioxidants on oxidation parameters and atherogenesis in hyperlipidaemic rabbits
84. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor deficient mice
85. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice
86. A rapid screening test to determine the antioxidant potencies of natural and synthetic antioxidants
87. Prevention of tocopherol-mediated peroxidation of ubiquinol-10-free human low density lipoprotein
88. Antioxidants: A biological defence mechanism for the prevention of atherosclerosis
89. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty
90. Effects of probucol on vascutar remodeling after coronary angioplasty
91. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apotipoprotein-E-deficient mice
92. Evidence of hypoxic areas within the arterial wall in vivo
93. Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells
94. Selective inhibition by probucol of vascular cell adhesion molecule-1 (VCAM-1) expression in human vascular endothelial cells
95. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
96. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation
97. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
98. Role of endothelial nitric oxide synthase in endothelial cell migration
99. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E)
100. Vitamin C suppresses oxidative lipid damage in vivo, even in the presence of iron overload
101. Ascorbate is depleted by smoking and repleted by moderate supplementation: A study in male smokers and nonsmokers with matched dietary antioxidant intakes
102. Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome
103. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin
104. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydro-biopterin
105. Nitric oxide and postangioplasty restenosis: Pathological correlates and therapeutic potential
106. Relation of preservation of nitric oxide-dependent coronary vasomotor function to plasma vitamin C concentrations in cardiac transplant recipients